Publications
117
Citations
686
Est. group size
~37
Recurring co-author estimate
Active years
17
Publishing since 2010
Arjun Mittra's work focuses on early-phase (Phase I) clinical trials testing new cancer drugs in patients with advanced solid tumors, including targeted therapies like PARP inhibitors, HER2-directed antibody-drug conjugates, and immune checkpoint inhibitors. A recurring interest is using biomarkers and pharmacodynamic studies (measuring how drugs affect tumor biology in real time) to understand which patients respond to treatment and why some tumors resist therapy. This research combines drug development with genomic and immune-based analysis of cancer.
Publication output has grown substantially over the last decade, especially since 2022, rising from a handful of papers per year to over 30 by 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Topoisomerase 1 and DNA damage: Pharmacodynamic responses and mechanism of trastuzumab deruxtecan in HER2- expressing advanced solid tumors.
Journal of Clinical Oncology · 2026
- HER2-independent antitumor and pharmacodynamic responses to trastuzumab deruxtecan in patients with advanced solid tumors.
Journal of Clinical Oncology · 2026
- Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors
JCO Precision Oncology · 2025
- Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
Cancer Chemotherapy and Pharmacology · 2023
- Abstract B037: A pharmacodynamic pilot study of DS8201a in patients with HER2 expressing advanced solid tumors
Molecular Cancer Therapeutics · 2023
- Supplementary Data from Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
2023
- Supplementary Data from Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
2023
- Data from Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
2023
- Data from Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
2023
- Characterizing the landscape of RING-type E3 ubiquitin transferase-altered (<i>RNF43 </i>alt) colorectal cancer (CRC) and defining unique subsets with potential therapeutic vulnerabilities in microsatellite instability-high (MSI-H) CRC.
Journal of Clinical Oncology · 2023
- Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma
Cancers · 2022
- Abstract CT147: Phase 1 study of recombinant interleukin 15 (rhIL-15) in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers
Cancer Research · 2022
- Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
Clinical Cancer Research · 2021
- Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute
The Oncologist · 2021
- Abstract CT115: Phase I trial of the triplet berzosertib (M6620, VX-970), veliparib and cisplatin (BVP) in patients with advanced solid tumors
Cancer Research · 2021
- Journal of Clinical Oncology×33
- Cancer Research×5
- Molecular Cancer Therapeutics×4
- Regular and Young Investigator Award Abstracts×3
- Clinical Cancer Research×2
- Anne M. Noonan
Medicine · The Ohio State University
- Anita Turk
Medicine · Indiana University
- Patrick W. Underwood
Medicine · The Ohio State University
- Ashish Manne
Medicine · The Ohio State University
- Pannaga Malalur
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile